The US Food and Drug Administration is moving slowly in drawing regulatory boundaries for CBD businesses. Members of Congress have called for clarity, but the FDA says it has no plans to give cannabis derivatives the green light
Get 7 days of access to industry updates through our news analysis and regulatory alerts
"*" indicates required fields